This study aims to treat your cancer and closely resembles routine care that would be received regardless of participating on a research study. To participate on the study, you will frequently meet with a member of the study team in addition to your oncology care team. The study also involves labs, Imaging (CT or MRI); physical exams; completion of questionnaires (paper surveys): before treatment begins; at the beginning of each cycle of treatment (until cycle 11); and after treatment ends. The study has 2 groups: a computer will be used to assign you to one of the groups (randomization). If you are in group 1: you will get the combination of olaparib and temozolomide. If you are in group 2: your will get trabectedin or pazopanib. After treatment, your doctor will continue to follow your condition for up to 5 years.